Paris, France – August 4, 2021
Imageens showcased its presence at the prestigious ‘Journées Francophones de Radiologie’ (JFR) 2021 by presenting its cutting-edge Cardioinspect technology. The event provided a platform to unveil the core capabilities of this groundbreaking solution.
Cardioinspect is poised to redefine cardiovascular risk assessment by introducing an innovative approach, especially for patients currently classified at intermediate risk., Cardioinspect based Artfun+ technology evaluates patients’ cardiovascular stiffness, accurately measuring their actual vascular age, thus enabling precise predictions of mortality and cardiovascular events up to 8.5 years in advance.
The effectiveness and reliability of the Cardioinspect technology have been rigorously validated through an extensive international study. The Cardioinspect technology has been implemented in over 33 prominent medical centers worldwide, encompassing countries such as France, the USA, and England.
A significant milestone in the evolution of Cardioinspect was reached through a strategic partnership between Imageens and the Assistance Publique – Hôpitaux de Paris (APHP), one of the largest and most prestigious hospital networks in Europe.
Regarding this strategic partnership, CEO of Imageens, remarked, ‘We are thrilled to collaborate with APHP to enhance CardioInspect and pave the way for the development of innovative clinical decision software tools. This partnership underscores our commitment to harnessing groundbreaking technology to empower healthcare professionals and revolutionize patient outcomes.’
Imageens is a Paris-based Healthtech company founded in 2017, focusing on the prevention and early diagnosis of cardiovascular diseases (CVD). Since its inception, Imageens has been immersed in international DeepTech and established with the goal of developing market-ready medical image processing software based on over 10 years of technical and clinical research conducted by world-class research institutions such as Sorbonne Université, the AP-HP, and Johns Hopkins.
From the outset, Imageens has demonstrated its capability to harness advanced AI in creating cutting-edge medical software. This innovation has earned recognition through several prestigious French innovation competitions and multiple innovation labels.
Today, Imageens leads the charge in the rapidly growing field of AI in cardiovascular health and medical imaging. The company possesses the world’s most clinically validated technology for analyzing arterial function through MRI, deploying this technology alongside other AI components to revolutionize treatment decisions in cardiovascular health and beyond. Learn more at www.Imageens.com
Le congrès JFR 2023 est un congrès international axé sur l’imagerie médicale.
Le congrès attirera plus de 12 000 participants, rassemblant certaines des entreprises les plus établies, innovantes et reconnaissables ainsi que des acteurs clés dans le secteur.